Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other Non-Current Assets for 10 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 228.19% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, up 228.19% year-over-year, with the annual reading at $1.7 million for FY2025, 228.19% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $1.7 million at Cartesian Therapeutics, down from $5.6 million in the prior quarter.
  • The five-year high for Other Non-Current Assets was $6.1 million in Q1 2025, with the low at $518000.0 in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $1.9 million, with a median of $1.4 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets dropped 13.94% in 2023, then skyrocketed 339.58% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $1.4 million in 2021, then grew by 16.03% to $1.6 million in 2022, then fell by 13.94% to $1.4 million in 2023, then plummeted by 62.38% to $518000.0 in 2024, then surged by 228.19% to $1.7 million in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $1.7 million, $5.6 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.